Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E16.22 EPS (ttm)9.77 Insider Own0.20% Shs Outstand762.48M Perf Week-2.09%
Market Cap120.86B Forward P/E12.70 EPS next Y12.48 Insider Trans-2.33% Shs Float746.25M Perf Month-9.74%
Income7.43B PEG2.05 EPS next Q2.79 Inst Own81.00% Short Float1.11% Perf Quarter-4.28%
Sales22.47B P/S5.38 EPS this Y35.20% Inst Trans0.02% Short Ratio2.96 Perf Half Y-1.82%
Book/sh40.12 P/B3.95 EPS next Y9.95% ROA10.10% Target Price189.41 Perf Year6.63%
Cash/sh45.95 P/C3.45 EPS next 5Y7.93% ROE25.90% 52W Range137.31 - 176.85 Perf YTD-0.45%
Dividend4.00 P/FCF20.19 EPS past 5Y13.60% ROI12.50% 52W High-10.37% Beta1.09
Dividend %2.52% Quick Ratio3.70 Sales past 5Y7.60% Gross Margin81.40% 52W Low15.44% ATR2.57
Employees17900 Current Ratio4.00 Sales Q/Q5.90% Oper. Margin40.70% RSI (14)28.33 Volatility1.40% 1.49%
OptionableYes Debt/Eq1.10 EPS Q/Q14.90% Profit Margin33.10% Rel Volume1.28 Prev Close161.50
ShortableYes LT Debt/Eq0.93 EarningsOct 27 AMC Payout36.30% Avg Volume2.80M Price158.51
Recom2.40 SMA20-4.77% SMA50-6.61% SMA2000.89% Volume3,531,800 Change-1.85%
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Oct-23-16 03:27PM  Index funds can be inferior to active funds in two crucial ways at MarketWatch
10:35AM  Top Health Care Earnings Coming Next Week at 24/7 Wall St.
Oct-21-16 05:03PM  Sanders urges Californians to approve drug price ballot measure Reuters
10:47AM  Will Amgen (AMGN) Sustain its Earnings Beat Trend in Q3?
10:00AM  Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals
Oct-20-16 04:19PM  Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients PR Newswire
04:03PM  Amgen Partner Kite Not 'A One-Trick Pony'; Pipeline Grows In 2017
10:29AM  7 Drug Stocks to Consider as Biosimilars Pick Up Pace
09:58AM  Biotech Stocks: Do Earnings Even Matter Anymore? at
09:55AM  Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains at 24/7 Wall St.
08:05AM  What Biogen Is Doing that Put It in Good Favor with Analysts
Oct-19-16 09:07AM  3 Stocks to Supplement Your Social Security Benefits at Motley Fool
08:05AM  Why Vertex Lowered Its Guidance for Orkambi
Oct-18-16 12:06PM  [$$] J&J prepares for drug price war with Pfizer at Financial Times
09:41AM  Pfizer to Launch Remicade Biosimilar in U.S. in November
Oct-17-16 06:16PM  Pfizer to launch cheaper version of J&J immune drug Remicade
03:34PM  Amgen: Indicators Are Mixed, What Could Be Next?
10:21AM  Amgen to Pay $1 Per Share 4Q Dividend (AMGN) at Investopedia
Oct-16-16 12:56PM  High Pressure Economy Means Future-Focused Investing
Oct-14-16 04:32PM  Better Buy: Amgen Inc. vs. Gilead Sciences, Inc. at Motley Fool
04:10PM  AMGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:05PM  Amgen Announces 2016 Fourth Quarter Dividend PR Newswire
04:00PM  Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors PR Newswire
11:04AM  How Valeant Is Trying to Improve Its Profit Margins
Oct-13-16 01:45PM  19 Bay Area companies to watch at this year's S.F. BIO Investor event at
Oct-12-16 05:49PM  Martin Whitman's Top Recent Investments
12:15PM  Trading the biotech sell-off
11:09AM  Amgen, Inc. : AMGN-US: Dividend Analysis : August 17th, 2016 (record date) : By the numbers : October 12, 2016
07:10AM  Short Sellers Have Mixed Views on Major Biotechs at 24/7 Wall St.
Oct-11-16 05:59PM  Final Trade: AMGN, OLED, & more
05:15PM  Biotech bloodbath
04:59PM  Biotech Stocks Smacked For Biggest Decline in 3 1/2 Months at The Wall Street Journal
12:20PM  Amgen Reports Positive Cancer Drug Results (AMGN) at Investopedia
09:25AM  Teva Acquires Rights to Oncology Biosimilar Candidates
08:21AM  3 Top Biotech Stocks to Buy Right Now at Motley Fool
Oct-10-16 09:09AM  New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin PR Newswire
Oct-07-16 03:51PM  Following Kite Pharma's Positive Top-Line Data, Focus Turns To Commercial Outlook
12:22PM  6 Healthcare Stocks Investors Can't Miss in Q3 Earnings
11:51AM  Will Biogen Join Gilead in the Disappointment Club? at
10:36AM  Pfizer to Sell Hospira Infusion Unit to ICU Medical for $1B
09:11AM  3 Ways Rockwell Medical Inc. Could Turn Things Around at Motley Fool
Oct-06-16 06:50PM  Amgen Set To Appear at ESMO Congress (AMGN) at Investopedia
Oct-05-16 04:10PM  New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress PR Newswire
03:00PM  Amgen Inks Oncology, Neuroscience Deals (AMGN) at Investopedia
Oct-04-16 04:00PM  Amgen To Participate In Citi Biotech R&D Conference Call PR Newswire
09:53AM  Amgen Announces Publication of Blincyto Phase I/II Data
Oct-03-16 04:09PM  Study Results Published In Journal of Clinical Oncology Show BLINCYTO® (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Ly PR Newswire
03:13PM  3 Top Biotech Stocks to Buy in October at Motley Fool
01:07PM  Amgen Signs Agreement With Exosome Dignostics (AMGN) at Investopedia
11:05AM  $1.5B deal: AstraZeneca licenses experimental Crohn's disease drug to Allergan at
11:03AM  Gilead: Will New HIV Drugs Overshadow Hep C Worries? at
09:48AM  Friends or Foes: Amgen and Novartis (AMGN, NVS) at Investopedia
09:33AM  Amgen Expands New Drugs Into Indian Market (AMGN, RDY) at Investopedia
02:21AM  AstraZeneca licenses inflammatory disease candidate to Allergan Reuters
Oct-02-16 02:12PM  3 Healthcare Stocks That Could Raise Their Dividends at Motley Fool
05:00AM  Big Pharma vs Big Pharma in court battles over biosimilar drugs Reuters
Oct-01-16 01:15AM  Novartis psoriasis drug maintains efficacy after 4 years - study Reuters
Sep-30-16 06:03PM  Could Growing HIV Franchise Drive Gilead Sciences Valuation?
04:54PM  Prothena Builds On Psoriasis Science For Arthritis Treatment
02:37PM  Chardan Rates Regeneron A Sell, Advises Caution
11:52AM  Buy These 4 Stocks and Beat Biotech's Slump
11:10AM  Why Arrowhead Pharmaceuticals Stock Spiked Today at Motley Fool
10:15AM  Amgen (AMGN) Migraine Drug Hits Phase III Primary Endpoint
09:38AM  ETFs with exposure to Amgen, Inc. : September 30, 2016
Sep-29-16 11:21PM  Amgens Kyprolis Fails in Trial (AMGN) at Investopedia
05:39PM  Amgens Backup Plan for Kyprolis (AMGN) at Investopedia
05:16PM  [$$] Zymeworks Gains Immuno-Oncology Drugs Through Daiichi Sankyo Deal at The Wall Street Journal
05:06PM  Long Wait for Biosimilar Amjevita (AMGN) at Investopedia
04:40PM  Stocks skid as drugmakers fall, then bank woes deepen losses
04:29PM  Amgen Maintains Migraine Drug Lead (AMGN) at Investopedia
04:09PM  Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market
03:48PM  Amgen Arrowhead Announce Two Cardiovascular Collaborations (AMGN, ARWR) at Investopedia
02:00PM  Arrowhead (ARWR): Collaborations with Amgen for Two Cardiovascular Programs
11:45AM  Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships
11:16AM  CORRECTED: mgen and Arrowhead Pharma agree 2 cardiovascular collaborations at MarketWatch
10:03AM  7 Healthcare Stocks in Focus on World Heart Day
09:56AM  Amgen, Arrowhead team up on gene-therapies for heart disease
08:32AM  Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : September 29, 2016
07:36AM  Amgen and Arrowhead to develop gene-therapies for heart disease
07:30AM  Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations PR Newswire
Sep-28-16 05:50PM  Amgen Reports Positive Results for Trial (AMGN) at Investopedia
04:30PM  Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study PR Newswire
12:25PM  Four Stellar Stocks to Beat the Biotech Slump at TheStreet
10:02AM  Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
08:51AM  Biotech Stock Roundup: Amgen's Kyprolis Disappoints, Array Up on Cancer Data
07:10AM  Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III
Sep-27-16 08:32PM  Amgen's Biosimilar Gets FDA Approval (AMGN, ABBV) at Investopedia
07:10PM  Third Value Fund Avenue Buys 3 Stocks in 3rd Quarter
05:13PM  Amgen's Osteoporosis Drug Crosses a Hurdle (AMGN) at Investopedia
04:26PM  Here's Why Ligand Pharmaceuticals Inc Is Plunging Today at Motley Fool
04:23PM  Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade
04:22PM  Shares of Ligand plunge 12% after Amgen drug misses study goal at CNBC
12:42PM  Why Wells Fargo, Gilead, Newfield, Amgen, and Chesapeake Energy Are Trending at Insider Monkey
12:40PM  Stocks Extend Gains; Facebook Up On Positive Analyst Chatter
11:38AM  Stocks Up After 1st Presidential Debate; Why Tesla Looks Healthiest In Weeks
11:23AM  The Drug Price Increase Debate: Separating The Winners From The Losers
11:15AM  Amgen (AMGN) Stock Slides, RBC: Clarion Trial May Have Failed Due to Design
11:00AM  Amgen's multiple myeloma drug falls short in new-patient study Reuters
10:44AM  Amgen: The Blame Game at
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy's Laboratories Ltd.; and Nuevolution AB. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM